Boston Scientific
Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets medical devices used in interventional specialties to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Its products serve physicians and other medical professionals, hospitals,… From the company’s description.
In fiscal 2025, Boston Scientific reported revenue of $20.07B, up 19.9% from fiscal 2024, and net income of $2.89B. Its operating margin was 18.0%, and operations generated $4.53B in cash. Over the twelve months to Jun 30, 2026, revenue was $21.00B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Boston Scientific does
In the company’s own words
Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets medical devices used in interventional specialties to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Its products serve physicians and other medical professionals, hospitals, clinics, outpatient facilities and medical offices. The company operates two reportable segments, MedSurg and Cardiovascular, with offerings spanning endoscopy, urology and neuromodulation as well as interventional cardiology, vascular therapies, electrophysiology, cardiac rhythm management and other cardiovascular treatments. Major product lines include WATCHMAN left atrial appendage closure devices, FARAPULSE pulsed field ablation systems, SYNERGY coronary stents, and LithoVue single-use ureteroscopes. Boston Scientific sells in 127 countries, primarily through direct sales organizations, and also uses distributors and dealers in selected markets. It had approximately 59,000 employees as of December 31, 2025. Its website is www.bostonscientific.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MARLBOROUGH, MA
- Fiscal year end
- December
- CIK
- 885725
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Boston Scientific — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Boston Scientific · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Boston Scientific’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Boston Scientific’s bonds, as funds hold them
Funds report holding 16 issues of Boston Scientific’s debt, $438.66M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.30%, maturing 2026 to 2049.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Boston Scientific and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Boston Scientific's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Boston Scientific's last four quarterly filings that the numbers alone won't show?”